CALC CalciMedica, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY34.5%
TTM EPS YoY152.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-763.3%
ROA-103.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets70.4%
Debt / equity0.00x
Current ratio4.96x
Interest coverage-14.15x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio21.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $15.23M | $14.48M | $15.86M | $8.35M | $18.90M |
| SG&A expense | $7.89M | $9.73M | $22.22M | $5.84M | $17.04M |
| Operating income | -$23.12M | -$24.20M | -$38.08M | -$14.19M | -$35.95M |
| Interest expense | $1.42M | $0 | — | — | — |
| Pretax income | -$29.56M | -$13.70M | — | — | — |
| Income tax | $0 | $0 | $1,000 | $1,000 | — |
| Net income | -$29.56M | -$13.70M | -$34.36M | -$7.82M | -$35.82M |
| EBITDA | -$23.07M | -$24.15M | -$38.02M | -$14.14M | -$35.43M |
| EPS (basic) | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 |
| EPS (diluted) | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 |
| Weighted avg. shares (diluted) | 15.01M | 11.25M | 4.49M | 82,245 | 21.20M |
| Banking | |||||
| Noninterest income | $713,000 | $1.01M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $11.52M | $7.93M | $5.53M | $1.33M | $13.36M |
| Short-term investments | $1.50M | $10.73M | $5.71M | $0 | $50.31M |
| Current assets | $13.53M | $19.66M | $11.61M | $1.73M | $67.08M |
| PP&E, net | $50,000 | $119,000 | $167,000 | $147,000 | $1.98M |
| Total assets | $13.59M | $19.79M | $12.19M | $3.35M | $69.09M |
| Current liabilities | $3.78M | $3.68M | $4.03M | $4.78M | $4.06M |
| Total liabilities | $20.23M | $5.38M | $4.03M | $12.58M | $4.07M |
| Shareholders' equity | -$6.64M | $14.41M | $8.16M | -$71.30M | -$63.99M |
| Shares outstanding | 3.09M | 13.48M | 5.75M | 84,165 | 21.36M |
| Cash flow statement | |||||
| Operating cash flow | -$21.18M | -$21.15M | -$25.73M | -$11.76M | -$31.50M |
| Capital expenditure | $28,000 | $8,000 | $78,000 | $4,000 | $488,000 |
| Free cash flow | -$21.21M | -$21.15M | -$25.81M | -$11.76M | -$31.99M |
| Investing cash flow | $9.55M | -$4.42M | $8.88M | -$4,000 | $10.75M |
| Financing cash flow | $15.21M | $27.97M | $20.90M | $8.48M | $695,000 |
| Depreciation & amortization | $46,000 | $58,000 | $58,000 | $52,000 | $519,000 |
| Stock-based compensation | $2.97M | $2.31M | $12.04M | $1.81M | $5.38M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.